Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dong, Yaowu
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Recruiting	3	510	Europe, Canada, Japan, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	10/26	02/27
NCT06046391: Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult	Recruiting	2	180	RoW	LP-003 dose 1, LP-003 dose 2, Placebo	Longbio Pharma	Seasonal Allergic Rhinitis	07/24	12/24
NCT06861101: Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults	Recruiting	2	320	RoW	JT002 Nasal spray, Placebo	Shanghai JunTop Biosciences Co., LTD	Seasonal Allergic Rhinitis	08/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dong, Yaowu
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Recruiting	3	510	Europe, Canada, Japan, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	10/26	02/27
NCT06046391: Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult	Recruiting	2	180	RoW	LP-003 dose 1, LP-003 dose 2, Placebo	Longbio Pharma	Seasonal Allergic Rhinitis	07/24	12/24
NCT06861101: Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults	Recruiting	2	320	RoW	JT002 Nasal spray, Placebo	Shanghai JunTop Biosciences Co., LTD	Seasonal Allergic Rhinitis	08/25	12/25